CombiGene
2.58
SEK
-0.77 %
COMBI
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
-0.77%
+24.04%
-6.52%
-20.37%
-4.09%
+7.05%
-77.91%
-88.32%
-97.31%
combigene.com
CombiGene's vision is to give patients affected by severe diseases the opportunity for a better life through gene therapy and other forms of advanced treatments. The company's operations have three focus areas: in-licensing of new assets, development of these assets to proof-of-concept, and out-licensing of the assets to a strategic partner for continued development and commercialization. CombiGene is based in Stockholm.
Revenue
5.54M
EBIT %
-696.75 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
COMBI
Daily low / high price
2.42 / 2.72
SEK
Market cap
51.09M SEK
Turnover
25.01K SEK
Volume
9.9K
Financial calendar
Extraordinary general meeting
10.12.2024
Annual report
14.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Orpahazyme AS | 10.0 % | 10.0 % |
Jan Ivar Nordqvist | 9.5 % | 9.5 % |
Avanza Pension | 6.5 % | 6.5 % |
M&L Industriförvaltning AB | 3.3 % | 3.3 % |
Thoren Tillväxt AB | 2.5 % | 2.5 % |
Nordnet Pensionsförsäkring AB | 2.3 % | 2.3 % |
Ferstad, Arne | 1.5 % | 1.5 % |
Molse, Oliver | 1.3 % | 1.3 % |
Olsson, Per Magnus | 1.3 % | 1.3 % |
Thomassen Skaar, Christian | 1.3 % | 1.3 % |
ShowingAll content types
Shareholders’ proposal for election of Board of Directors
Interim report January – September 2024 for CombiGene AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools